Disease Annotations for Variants in Personal Genomes

个人基因组变异的疾病注释

• 批准号: 8002144
• 负责人: Karen Louise Eilbeck
• 金额: $ 14.92万
• 依托单位: FABRIC GENOMICS INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-30 至 2012-03-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8002144
• 关键词: Area; Arts; Basic Science; Cardiovascular Diseases; Categories; Clinical; Collection; Computer software; Data; Data Set; Development; Disease; Ensure; Foundations; Generations; Genes; Genetic; Genetic Variation; Genome; Genomics; Goals; Health; Hereditary Disease; Human; Individual; Learning; Literature; Location; Manuals; Medicine; Molecular Diagnostic Testing; Mutation; Nature; Ontology; Other Genetics; Phase; Process; Proteins; Protocols documentation; Public Health; Publishing; Reporting; Reproductive Health; Research; Resources; Solutions; Structural Genes; System; Technology; Terminology; Testing; Variant; Vocabulary; Work; arm; base; biomedical ontology; clinically relevant; commercialization; disease classification; genome sequencing; innovation; interoperability; prognostic; prototype; public health relevance; research clinical testing; tool; tool development; tumorigenesis; usability

DESCRIPTION (provided by applicant): High-throughput sequencing technologies are beginning to deliver complete individual genome sequences. However, significant barriers still obstruct the use of these data for basic research and in clinical evaluation for personalized medicine. One major barrier is the absence of tools for variant annotation with respect to disease. Our goal is to overcome this barrier by creating for sequence variants a suite of tools similar to those that exist for gene annotation. Although disease, gene and sequence ontolgies already exist, systematically interrelating (harmonizing) them to one another in a manner that will support effective variant annotation is a major task. We will use state of the art protocol for biomedical ontology development, ensuring interoperability and usability to achieve this goal. The research proposed in this application has three aims. In Phase I we will harmonize and interrelate existing ontologies for variant and disease annotation, with a specific focus on cardiovascular disease (CVD). In Aim 2 we will curate an existing CVD gene collection compiled at Omicia Inc. consisting of 336 CVD disease genes to the harmonized ontology. In Aim 3 we will annotate the variants and implications of each variation for ten personal genomes. Our plan is to begin with a proof-of-concept project to develop an ontology for annotating personal sequence variants in genes implicated in CVD. In phase II we intend to expand the ontology to a broader coverage of disease, utilizing the lessons we learn from phase I. This firm logical foundation will allow us to build a suite of commercial strength software for variant annotation to provide a much needed tool for personal genomics. PUBLIC HEALTH RELEVANCE: This project will produce a modular, harmonized ontology for the description of personal genomic sequence variants with respect to cardiovascular disease (CVD). This will in turn provide a means to generate detailed, clinically relevant genetic-signature reports. This work will be preformed in partnership with Omicia Incorporated. Omicia's goal is to provide content and analysis tools for molecular diagnostic tests using personal genome sequences. The tools produced by this project will promote better public health and provide significant commercial opportunities.

描述（由申请人提供）：高通量测序技术开始提供完整的个体基因组序列。然而，重大障碍仍然阻碍了这些数据用于基础研究和个性化医疗的临床评价。一个主要障碍是缺乏关于疾病的变异注释工具。我们的目标是通过为序列变异创建一套类似于基因注释的工具来克服这一障碍。尽管疾病、基因和序列个体学已经存在，但以支持有效变异注释的方式将它们系统地相互关联（协调）是一项主要任务。我们将使用最先进的协议进行生物医学本体开发，确保互操作性和可用性，以实现这一目标。本申请中提出的研究有三个目的。在第一阶段，我们将协调和相互关联现有的变异和疾病注释的本体，特别关注心血管疾病（CVD）。在目标2中，我们将策划一个在Omicia Inc.编译的现有CVD基因集合。由336个CVD疾病基因组成的协调本体。在目标3中，我们将注释十个人基因组的变异和每个变异的含义。我们的计划是开始的概念验证项目，以开发一个本体注释的个人序列变异的基因牵连在CVD。在第二阶段，我们打算利用我们从第一阶段学到的教训，将本体论扩展到更广泛的疾病覆盖范围。这一坚实的逻辑基础将使我们能够构建一套具有商业实力的变异注释软件，为个人基因组学提供急需的工具。 公共卫生相关性：该项目将产生一个模块化的，协调的本体论，用于描述与心血管疾病（CVD）相关的个人基因组序列变异。这反过来将提供一种生成详细的、临床相关的遗传特征报告的方法。这项工作将与Omicia Incorporated合作进行。Omicia的目标是为使用个人基因组序列的分子诊断测试提供内容和分析工具。该项目产生的工具将促进改善公共卫生，并提供重要的商业机会。